Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. RenaissanceRe Holdings Ltd.
43.2% sales growth and 8.63% return on equity
RenaissanceRe Holdings Ltd. provides reinsurance and insurance products in the United States and internationally.
RenaissanceRe Holdings Ltd. sales growth this year is expected to be 11.2% and 13.6% for next year.
Year-on-year quarterly revenue growth grew by 24.1%, now sitting on 4.88B for the twelve trailing months.
RenaissanceRe Holdings Ltd.'s sales growth for the next quarter is 43.2%. The company's growth estimates for the ongoing quarter and the next is 282.7% and 488.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.63%.
RenaissanceRe Holdings Ltd.'s Stock Top and Bottom Yearly Value
RenaissanceRe Holdings Ltd.'s stock is valued at $167.20 at 15:57 EST, way below its 52-week high of $202.68 and way above its 52-week low of $113.27.
RenaissanceRe Holdings Ltd.'s Moving Average
RenaissanceRe Holdings Ltd.'s value is under its 50-day moving average of $170.81 and under its 200-day moving average of $175.17.
2. NVIDIA
49.8% sales growth and 28.82% return on equity
NVIDIA Corporation operates as a visual computing company worldwide. It operates in two segments, GPU and Tegra Processor.
NVIDIA sales growth this year is expected to be 51% and 20.4% for next year.
Year-on-year quarterly revenue growth grew by 56.8%, now sitting on 14.78B for the twelve trailing months.
NVIDIA's sales growth for the next quarter is 49.8%. The company's growth estimates for the ongoing quarter and the next is 48.1% and 40%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 28.82%.
NVIDIA's Stock Top and Bottom Yearly Value
NVIDIA's stock is valued at $520.53 at 15:57 EST, way under its 52-week high of $589.07 and way higher than its 52-week low of $180.68.
NVIDIA's Moving Average
NVIDIA's worth is below its 50-day moving average of $532.57 and way above its 200-day moving average of $472.14.
3. Thor Industries, Inc.
56.7% sales growth and 12.55% return on equity
Thor Industries, Inc. designs, manufactures, and sells recreational vehicles (RVs), and related parts and accessories in the United States, Canada, and Europe.
Thor Industries, Inc. sales growth this year is expected to be 26.6% and 4.2% for next year.
Year-on-year quarterly revenue growth grew by 17.5%, now sitting on 8.55B for the twelve trailing months.
Thor Industries, Inc.'s sales growth for the next quarter is 56.7%. The company's growth estimates for the ongoing quarter and the next is 125.8% and 302.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.55%.
Thor Industries, Inc.'s Stock Top and Bottom Yearly Value
Thor Industries, Inc.'s stock is valued at $95.17 at 15:57 EST, way under its 52-week high of $121.33 and way higher than its 52-week low of $32.30.
Thor Industries, Inc.'s Moving Average
Thor Industries, Inc.'s value is above its 50-day moving average of $90.96 and below its 200-day moving average of $99.73.
4. XP Inc.
47% sales growth and 32.64% return on equity
XP Inc. operates technology-driven financial services platform that provides financial products and services in Brazil.
XP Inc. sales growth this year is anticipated to be 66.1% and 37.6% for next year.
Year-on-year quarterly revenue growth grew by 54.9%, now sitting on N/A for the twelve trailing months.
XP Inc.'s sales growth for the next quarter is 47%. The company's growth estimates for the current quarter and the next is 33.3% and 42.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 32.64%.
XP Inc.'s Stock Top and Bottom Yearly Value
XP Inc.'s stock is valued at $37.93 at 15:57 EST, way under its 52-week high of $52.94 and way higher than its 52-week low of $15.50.
XP Inc.'s Moving Average
XP Inc.'s value is under its 50-day moving average of $41.00 and way under its 200-day moving average of $43.08.
Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
